Merck and Prizer
...y on the market and doesn't make patients put on excess weight. Consumer brands like Visine, Listerine, BenGay, and Certs will likely continue to boost profits. Revenues increased 40% to $45,188 million in 2003 and 12% to $32,373 million in 2002. In 2003, Revenue increases in 2002 were due primarily to newly launched products, new indications for existing products and sales volume growth of our pharmaceutical products. Revenues in the U.S. grew 30% to $26,844 million in 2003 and 12% to $20,613 million in 2002. International revenues grew 56% to $18,344 million in 2003 and 12% to $11,760 million in 2002. Revenues exceeded $500 million in each of ten countries outside the U.S. in 2003 and in each of seven countries outside the U.S. in 2002. Cost of sales increased 143% in 2003 and 6% in 2002 while revenues increased 40% in 2003 and 12% in 2002. Sales of this inventory were completed by the end of 2003. Overall, 2003 cost of sales was impacted by: „« Incremental cost of sales ($2,820 million in 2003) from the sale of inventory acquired from Pharmacia adjusted to fair value „« Change in product mix, given the addition of legacy Pharmacia¡¦s product portfolio, which has a higher product cost relative to legacy Pfizer¡¦s product po...